An innovative service company focusing on the field of drug quality control

News

Contact Us

You are here:Home >> News >> Industry information...

Industry information

​​Consistency Evaluation of Generic Drugs: June 2025 Update

Time:2025-07-09 Views:0
  China‘s consistency evaluation of generic drugs continues to deepen, driven by ​​policy incentives​​ and ​​technical optimizations​​, accelerating the industry‘s shift toward high-quality development. According to ​​Moshang Data​​, 27 drug varieties (covering 39 application numbers) submitted consistency evaluation applications in June 2025. The majority were ​​systemic anti-infectives​​, including:
  Ampicillin Sodium for Injection
  Faropenem Sodium Tablets
  Cefotaxime Sodium for Injection
  Amoxicillin-Clavulanate Dry Suspension.
  Concurrently, 30 drug varieties ​​passed consistency evaluations​​ in June, such as:Vitamin B6 Injection、Diprophylline       Injection、 Nicergoline Tablets、Epinephrine Hydrochloride Injection、Octreotide Acetate Injection
  Trihexyphenidyl Hydrochloride Table、Cefotaxime Sodium for Injection.
  Additionally, 245 drugs were ​​deemed to have passed​​ consistency evaluations, with ​​cardiovascular medications​​ ranking highest in proportion. Potassium Chloride Granules saw approvals from 7 manufacturers, while 22 varieties achieved ​​first-time approvals​​.
Policy-Driven Acceleration
Policy incentives have expedited the review and approval process. A dedicated ​​"green channel"​​ enables immediate review of consistency evaluation applications upon submission, significantly boosting pharmaceutical companies‘ engagement in these initiatives.

  Impurity Control: The Core of Quality Assurance
  ​​Impurity profiling​​ is pivotal to consistency evaluation, directly determining whether generic drugs achieve ​​substantial equivalence​​ to originators in quality, safety, and efficacy. China‘s Technical Requirements for Consistency Evaluation of Generic Drugs mandates ​​multi-batch comparative analysis​​ of impurity profiles between generics and reference listed drugs (RLDs), ensuring impurity levels ​​do not exceed those of RLDs​​.


  SZEB supplies comprehensive ​​impurity reference standards​​ to support efficient compliance with consistency evaluations.
  ​​Product Coverage​​: Process-related impurities, degradation products, and isomer mixtures.
​​  Certification​​: Full COA, H-NMR, MS, and HPLC data provided.
  ​​Explore our offerings​​: www.ex-biotech.com
​​  Contact​​: sales@ex-biotech.com